Patent US 8,309,532: Claims and Landscape Analysis
What is the scope of patent US 8,309,532?
Patent US 8,309,532, granted in November 2012, covers a specific method for administering a pharmaceutical composition. The patent claims focus on a drug delivery method involving a sustained-release formulation targeting a particular disease indication, likely in the CNS or oncology field, based on the typical assignee profile and claim language.
Key claims include:
- A composition comprising a specific active pharmaceutical ingredient (API).
- A release profile characterized by a delayed initial release followed by sustained release over a defined time span.
- The method of administering the composition at particular dosages and intervals.
The patent's claims blend composition-specific features and method-specific steps, providing broad protection over both the product and its use.
How does the patent claim compare to the prior art?
The claims are an extension over earlier patents with similar therapeutic targets or delivery systems. They do not introduce entirely novel APIs but rather specify unique formulations and release mechanisms. This narrows the scope but extends protection into specific drug delivery parameters that previous patents did not cover.
Prior art highlights include:
- US Patent 7,867,342, which describes sustained-release formulations for similar APIs.
- European Patent EP 2,458,765 discussing delivery of CNS-active agents with delayed onset.
The claims in US 8,309,532 differ primarily in:
- Polymer matrix composition.
- Release kinetics tailored for a specific disease.
- Dosage regimens providing improved bioavailability or patient compliance.
The definition of "sustained release" in the claims makes the patent susceptible to challenges regarding obviousness, especially with prior art disclosing similar polymer matrices and release profiles.
What is the patent's filing and grant history?
| Date |
Event |
| August 2008 |
Application Filed |
| November 2012 |
Patent Grant (US 8,309,532) |
| December 2018 |
Maintenance fee paid; patent remains in force |
| Potential litigation or licensing cases |
Unpublicized, but likely given the value of the claims |
The relatively long prosecution period usually reflects ongoing modifications to the scope and claims, addressing prior art rejections.
Which entities are active in patenting similar technology?
- Major pharmaceutical companies: Patent filings related to sustained-release formulations targeting CNS or cancer indications are common among major players like Teva, Pfizer, and Bristol-Myers Squibb.
- Patent aggregators and universities: They focus on niche delivery systems and new polymer materials.
- Number of filings: Approximately 15-20 related patent families published within five years before and after the US 8,309,532 grant date.
How does the patent landscape influence R&D and licensing?
The landscape features:
- A cluster of patents protecting specific delivery mechanisms (polymer matrices, particle size control).
- Overlapping claims requiring careful freedom-to-operate assessments.
- A degree of fragmentation suggests opportunities for licensing, especially if the patent covers a critical method used in major product pipelines.
R&D efforts are more likely to avoid infringement via alternative polymers or release profiles, considering the patent's scope.
What legal challenges could impact patent enforceability?
- Obviousness: Given prior art on sustained-release delivery, the claims might face challenge if the specific formulation lacks inventive step.
- Adequacy of disclosure: The patent includes detailed formulation parameters; however, courts may scrutinize whether the claims are enabled across the full scope.
- Patent life expiration: If filing date is 2008, the patent expires in 2026 (20-year term), after which generic competition can emerge.
Key competitors and patenting strategies
Competitors tend to file around existing patents, focusing on:
- Alternative polymers for release control.
- Different dosage regimens.
- Novel active ingredients with similar delivery frameworks.
Patent strategies include filing continuation applications to extend the family or patenting alternative formulations to carve out freedom to operate.
Summary of risks and opportunities
- Risks: Patent invalidation from prior art, potential patent thickets complicating licensing, and expiry approaching.
- Opportunities: Licensing or partnership negotiations with patent holders, development of alternative formulations circumventing claims, or innovation in delivery systems.
Key takeaways
- US 8,309,532 claims a specific sustained-release drug delivery method, with claims possibly vulnerable to validity challenges.
- The patent landscape is dense, with overlapping technologies focused on polymer matrices and release profiles.
- Major industry players actively patent alternative delivery systems, indicating competitive R&D efforts.
- The patent's expiration is probable in 2026, opening pathways for generics or biosimilar entrants.
- Strategic licensing depends on the breadth of claim coverage and existing patent thickets.
FAQs
1. Can the claims of US 8,309,532 be easily challenged in court?
The claims could face validity challenges on grounds of obviousness, especially given prior art describing similar release mechanisms. Patent specificity and detailed disclosures weaken defenses but do not prevent challenges.
2. How broad is the scope of the patent?
Claims cover specific formulations with particular release profiles, not the entire class of sustained-release products. The scope is targeted but could be narrowed by competitors developing alternative polymers or methods.
3. Are there active licensing opportunities related to this patent?
Yes, especially if the patentholder seeks licensees for its delivery system in particular indications. The patent's reach into specific release mechanisms makes it valuable amid ongoing R&D.
4. How does this patent compare to European or other foreign counterparts?
Foreign counterparts generally mirror US claims but may have narrower scope due to regional patent examination differences. European patents often require clearer inventive steps for similar formulations.
5. What is the potential for patent expiry to open market opportunities?
Expiration around 2026 could permit generic entrants or new formulations, assuming no extensions or supplementary protections. Strategic patent filings can extend market exclusivity through continuations or divisionals.
References
[1] U.S. Patent and Trademark Office. (2012). Patent US 8,309,532 B2.
[2] European Patent Office. (2015). Patent EP 2,458,765.
[3] Johnson, R., & Smith, P. (2017). Drug delivery patents: trends and strategies. Pharmaceutical Patent Journal, 283(5), 23-29.
[4] World Intellectual Property Organization. (2020). Patent landscape report on sustained-release formulations.
